Depression News and Research

Latest Depression News and Research

Serotonin transporter gene appears to increase one's risk for depression, PTSD: Study

There is a great deal of interest in factors that contribute to the vulnerability to developing post-traumatic stress disorder, or PTSD. One factor that appears to contribute to the heritable vulnerability to PTSD is a variation in the gene that codes for the serotonin transporter, also known as the serotonin uptake site. Having a shorter version of the serotonin transporter gene appears to increase one's risk for depression and PTSD after exposure to extremely stressful situations.

18 Jun 2010

Research examines relationship between body-image distortion and weight-loss behaviors

Normal weight and underweight teenage girls who falsely believe they are overweight are at significantly greater risk of succumbing to unnecessary and unsafe weight-loss behaviors than girls who can accurately assess their weight status, according to new research by a University of Illinois expert in eating disorders and body-image perception.

18 Jun 2010

Study finds anxiety/panic disorder as most-disabling psychiatric disorder associated with TS

An assessment of patients with adult Tourette syndrome (TS) to identify clinical factors that contribute to psychosocial and occupational disabilities resulting from the vocal or motor tics that define TS found that anxiety/panic disorder may be the most disabling psychiatric condition associated with the disorder.

18 Jun 2010

Possible mechanism identified for how lithium treats bipolar disorder

Lithium has been established for more than 50 years as one of the most effective treatments for manic depression, clinically termed bipolar disorder. However, scientists have never been entirely sure exactly why it is beneficial.

18 Jun 2010

Alkermes receives tentative schedule notification for FDA advisory committee meeting on VIVITROL sNDA

Alkermes, Inc. today announced that the U.S. Food and Drug Administration (FDA) has notified the company of the tentative scheduling of a Psychopharmacologic Drugs Advisory Committee meeting on September 16, 2010, for the review of the company's supplemental New Drug Application (sNDA) for VIVITROL® (naltrexone for extended-release injectable suspension) for opioid dependence.

18 Jun 2010

Study reveals increase of enzyme MAO-A in female brain during immediate postpartum period

Within the first week after giving birth, up to 70 percent of all women experience symptoms of the baby blues. While most women recover quickly, up to 13 percent of all new mothers suffer from symptoms of a clinical-level postpartum depression. Postpartum depression is defined as a major depressive episode starting within 4 weeks after delivery and is a significant public health problem. Postpartum blues represents a major risk factor for developing postpartum depression and severe postpartum blues symptoms can be viewed as a prodromal stage for postpartum depression.

17 Jun 2010

Positive results from Phase I clinical trial of GLYX-13 presented at NCDEU meeting

Naurex Inc., a clinical stage company developing innovative treatments for depression and other CNS disorders, today reported that it presented data at the NCDEU 50th Anniversary Meeting showing that its novel mechanism compound GLYX-13 appeared safe in a Phase I trial. GLYX-13 is a glycine site functional partial agonist selective modulator of the NMDA receptor that is being developed initially for use in depression as adjunctive therapy.

17 Jun 2010

Neurocrine Biosciences, Boehringer Ingelheim collaborate to develop GPR119 agonists for Type II diabetes

Neurocrine Biosciences, Inc. announced today that they have established a worldwide collaboration with Boehringer Ingelheim to research and develop small molecule GPR119 agonists for the treatment of Type II diabetes and other indications. The companies will work jointly to identify and advance candidates into pre-clinical development. Boehringer Ingelheim is responsible for the global development and commercialization of potential GPR119 agonist products.

17 Jun 2010

New book gives hope to women and families who are in difficult stages of anorexia treatment

Women and families struggling with an eating disorder or another addiction should never lose sight of the need to sustain the spirit, according to a new book by Jena Morrow, an author in recovery after more than 20 years with anorexia nervosa. Morrow, a behavioral health specialist at Timberline Knolls Residential Treatment Center, details a battle with anorexia that begins in early childhood in Hollow: An Unpolished Tale, recently released by Moody Publishers.

17 Jun 2010

Research findings shed light on risk factors, prevention strategies for suicide

Masculine ideals of strength coupled with strong family ties can help men combat depression and overcome thoughts of suicide, according to University of British Columbia research.

17 Jun 2010

Selection of candidate in oncology programme triggers EUR 2.5 million milestone payment to Evotec

Evotec AG today announced that it has achieved a milestone as part of its research alliance with Boehringer Ingelheim and will receive a payment of EUR 2.5 million. The milestone was achieved for the selection of a candidate compound for pre-development studies in an oncology programme.

17 Jun 2010

CAMFT listed in 2010 Associations Advance America Honor Roll

The California Association of Marriage and Family Therapists has been named to the 2010 Associations Advance America Honor Roll, a national awards competition sponsored by the American Society of Association Executives & The Center for Association Leadership, Washington, D.C.

16 Jun 2010

Stress-related psychiatric disorders more common among women: Study

There may be a biological reason why depression and other stress-related psychiatric disorders are more common among women compared to men. Studying stress signaling systems in animal brains, neuroscience researchers found that females are more sensitive to low levels of an important stress hormone and less able to adapt to high levels than males.

16 Jun 2010

Abbott, Neurocrine enter collaboration to develop, commercialize elagolix for endometriosis-related pain

Abbott and Neurocrine Biosciences, Inc. today announced that they have entered into a collaboration agreement to develop and commercialize elagolix for the treatment of endometriosis-related pain. Elagolix is a novel, first-in-class oral gonadotropin-releasing hormone (GnRH) antagonist, which has recently completed a phase IIb study in endometriosis. In addition to endometriosis, elagolix will be evaluated for the treatment of uterine fibroids.

16 Jun 2010

Many Huntington's disease patients suffer from weight loss, sleeping problems

An aggregating protein causes many of the symptoms of Huntington's disease, an incurable and frequently fatal brain disorder. Mosaic winner Ahmad Aziz discovered that the abnormal protein also aggregates in the hypothalamus, the part of the brain that regulates the autonomic nervous system and the endocrine system.

16 Jun 2010

FDA unveils safety reports on recently approved drugs, biologics

The U.S. Food and Drug Administration today unveiled a new source of information for patients and health care professionals on the safety of recently approved drugs and biologics.

16 Jun 2010

NexMed's NexACT-based topical psoriasis treatment bioequivalent to Talconex

NexMed, Inc., a specialty CRO with a pipeline of products based on the NexACT® technology, today announced results from a pre-clinical study showing that calcipotriene 0.005% and betamethasone dipropionate 0.064%, when formulated with NexACT®, results in a topical treatment which shows bioequivalecy in efficacy to Talconex®, one of the leading topical treatments marketed for patients with mild to moderate psoriasis.

16 Jun 2010

New data shows Ohio children with special health care needs have inadequate insurance coverage

A third of Ohio children with special health care needs have unstable or inadequate insurance coverage despite the fact that they may qualify for government health programs, according to a new data analysis by the Child Policy Research Center at Cincinnati Children's Hospital Medical Center.

16 Jun 2010

Bayer sues Teva, Barr in connection with oral contraceptive Gianvi

Today, Bayer HealthCare Pharmaceuticals Inc. and Bayer Schering Pharma AG sued Teva Pharmaceuticals USA, Inc., Barr Pharmaceuticals LLC, and Barr Laboratories, Inc. in the Northern District of Illinois (Chicago) for false advertising and patent infringement in connection with Teva's generic oral contraceptive, Gianvi™. Teva's product is sold as a generic version of Bayer HealthCare's leading oral contraceptive YAZ®.

16 Jun 2010

Kendle offers BNA imaging technology for monitoring brain electro-physiological network activity

Kendle, a leading, global full-service clinical research organization, today announced it now offers Brain Network Activation imaging providing a non-invasive platform for mapping, monitoring and understanding brain electro-physiological network activity in response to cognitive or physiological stimuli. The BNA imaging technology was developed by ElMindA, a medical technology development company based in Herzliya, Israel.

15 Jun 2010

Depression News and Research

Latest Depression News and Research

Serotonin transporter gene appears to increase one's risk for depression, PTSD: Study

Research examines relationship between body-image distortion and weight-loss behaviors

Study finds anxiety/panic disorder as most-disabling psychiatric disorder associated with TS

Possible mechanism identified for how lithium treats bipolar disorder

Alkermes receives tentative schedule notification for FDA advisory committee meeting on VIVITROL sNDA

Study reveals increase of enzyme MAO-A in female brain during immediate postpartum period

Positive results from Phase I clinical trial of GLYX-13 presented at NCDEU meeting

Neurocrine Biosciences, Boehringer Ingelheim collaborate to develop GPR119 agonists for Type II diabetes

New book gives hope to women and families who are in difficult stages of anorexia treatment

Research findings shed light on risk factors, prevention strategies for suicide

Selection of candidate in oncology programme triggers EUR 2.5 million milestone payment to Evotec

CAMFT listed in 2010 Associations Advance America Honor Roll

Stress-related psychiatric disorders more common among women: Study

Abbott, Neurocrine enter collaboration to develop, commercialize elagolix for endometriosis-related pain

Many Huntington's disease patients suffer from weight loss, sleeping problems

FDA unveils safety reports on recently approved drugs, biologics

NexMed's NexACT-based topical psoriasis treatment bioequivalent to Talconex

New data shows Ohio children with special health care needs have inadequate insurance coverage

Bayer sues Teva, Barr in connection with oral contraceptive Gianvi

Kendle offers BNA imaging technology for monitoring brain electro-physiological network activity

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Depression News and Research

Latest Depression News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in